The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

被引：0
|
作者：
Stadler, W. M.
Figlin, R. A.
Ernstoff, M. S.
Curti, B.
Pendergrass, K.
Srinivas, S.
Canfield, V.
Weissman, C.
Poulin-Costello, M.
Bukowski, R. M.
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] City Hope Comprehens Canc Ctr, Los Angeles, CA USA
[3] Dartmouth Med Sch, Lebanon, NH USA
[4] Providence Portland Med Ctr, Portland, OR USA
[5] Kansas City Canc Ctr, Overland Pk, KS USA
[6] Stanford Univ Hosp, Stanford, CA 94305 USA
[7] Canc Care Associates, Oklahoma City, OK USA
[8] New York Oncol Hematol, Latham, NY USA
[9] Bayer HealthCare, West Haven, CT USA
[10] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5036
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Sorafenib in Renal Cell Carcinoma
    Edeline, Julien
    Vauleon, Elodie
    Rioux-Leclercq, Nathalie
    Perrin, Christophe
    Vigneau, Cecile
    Bensalah, Karim
    Laguerre, Brigitte
    CANCER GROWTH AND METASTASIS, 2012, 5 : 35 - 47
  • [32] Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
    Xu K.Y.
    Wu S.
    Biomarker Research, 3 (1)
  • [33] Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non-Clear Cell Renal Cell Carcinoma
    Rodriguez Faba, Oscar
    Breda, Alberto
    Rosales, Antonio
    Palou, Joan
    Algaba, Ferran
    Maroto Rey, Pablo
    Villavicencio, Humberto
    EUROPEAN UROLOGY, 2010, 58 (02) : 307 - 310
  • [34] Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
    Moussa, Mohammad Jad
    Khandelwal, Jaanki
    Wilson, Nathaniel R.
    Malikayil, Kiran L.
    Surasi, Devaki Shilpa
    Bathala, Tharakeswara K.
    Lin, Yiyun
    Rao, Priya
    Tamboli, Pheroze
    Sircar, Kanishka
    Ajufo, Helen
    Elsayes, Khaled M.
    Shah, Amishi
    Johns, Andrew C.
    Goswami, Sangeeta
    Hasanov, Elshad
    Jonasch, Eric
    Msaouel, Pavlos
    Campbell, Matthew T.
    Alhalabi, Omar
    Tannir, Nizar M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [35] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma
    Hutson, Thomas
    Xing, Dongyuan
    Dutcus, Corina
    Baig, Mahadi
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 14 - 15
  • [36] Re: A Phase 2 Trial of Sunitinib in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2012, 188 (06): : 2146 - 2147
  • [37] Targeted therapies for non-clear renal cell carcinoma
    Eric A. Singer
    Gennady Bratslavsky
    W. Marston Linehan
    Ramaprasad Srinivasan
    Targeted Oncology, 2010, 5 : 119 - 129
  • [38] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 125 - 134
  • [39] Re: Sorafenib in advanced clear-cell renal cell carcinoma
    Karakiewicz, Pierre I.
    Hutterer, Georg
    EUROPEAN UROLOGY, 2007, 52 (01) : 279 - 280
  • [40] Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy
    Urman, Danielle
    Deshler, Leah
    Weise, Nicole
    Shabaik, Ahmed
    Derweesh, Ithaar
    Bagrodia, Aditya
    Rose, Brent
    Herchenhorn, Daniel
    McKay, Rana R.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : 660 - 668.e1
12345